ERBB2 and breast cancer: Early results from the clinical trial (NCT0321926) showed a tolerable safety profile and encouraging evidence of anti-tumor activity in patients with advanced HER2-positive cancers, including breast cancer, and preliminary evidence of clinical viability [222].